228 related articles for article (PubMed ID: 28416742)
1. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
[TBL] [Abstract][Full Text] [Related]
2. Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.
Imbs DC; El Cheikh R; Boyer A; Ciccolini J; Mascaux C; Lacarelle B; Barlesi F; Barbolosi D; Benzekry S
CPT Pharmacometrics Syst Pharmacol; 2018 Jan; 7(1):42-50. PubMed ID: 29218795
[TBL] [Abstract][Full Text] [Related]
3. Convection enhanced delivery of anti-angiogenic and cytotoxic agents in combination therapy against brain tumour.
Zhan W
Eur J Pharm Sci; 2020 Jan; 141():105094. PubMed ID: 31626962
[TBL] [Abstract][Full Text] [Related]
4. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
Cesca M; Morosi L; Berndt A; Fuso Nerini I; Frapolli R; Richter P; Decio A; Dirsch O; Micotti E; Giordano S; D'Incalci M; Davoli E; Zucchetti M; Giavazzi R
Mol Cancer Ther; 2016 Jan; 15(1):125-35. PubMed ID: 26494857
[TBL] [Abstract][Full Text] [Related]
6. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab improves the delivery and efficacy of paclitaxel.
Yanagisawa M; Yorozu K; Kurasawa M; Nakano K; Furugaki K; Yamashita Y; Mori K; Fujimoto-Ouchi K
Anticancer Drugs; 2010 Aug; 21(7):687-94. PubMed ID: 20559127
[TBL] [Abstract][Full Text] [Related]
8. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
Volk LD; Flister MJ; Chihade D; Desai N; Trieu V; Ran S
Neoplasia; 2011 Apr; 13(4):327-38. PubMed ID: 21472137
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
[TBL] [Abstract][Full Text] [Related]
11. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
Zhu W; Kato Y; Artemov D
PLoS One; 2014; 9(1):e86583. PubMed ID: 24466160
[TBL] [Abstract][Full Text] [Related]
14. Investigation of combination therapy modes of bevacizumab and paclitaxel for NSCLC in vivo.
Wang J; Shen H; Jiang Q; Shu Y
Pak J Pharm Sci; 2016 Mar; 29(2 Suppl):695-9. PubMed ID: 27113309
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
[TBL] [Abstract][Full Text] [Related]
16. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of
Awasthi N; Schwarz MA; Zhang C; Schwarz RE
Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
[TBL] [Abstract][Full Text] [Related]
20. Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.
Hutchinson LG; Mueller HJ; Gaffney EA; Maini PK; Wagg J; Phipps A; Boetsch C; Byrne HM; Ribba B
CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):636-645. PubMed ID: 27863175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
